Paul Hopper is the Founder of Chimeric Therapeutics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fourteen companies in the US, Australia and Asia. Previous and current Boards include Viralytics, Imugene, Prescient Therapeutics, Polynoma and Suda Medical. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.
Dr Lesley Russell
25+ years of senior international operational and leadership experience having worked at Amgen, Eli Lilly, Teva, and Cephalon.
As Chief Medical Officer and Chief Operating Officer Dr Russell has wide experience in the therapeutic areas of hematology/oncology, neurology, psychiatry, pain, inflammation, respiratory medicine and stem cell therapy.
Extensive knowledge and experience with new drug development along with CAR-T therapies.
Non-Executive Director of Enanta Pharmaceuticals and Imugene Ltd.
Ms Leslie Chong
21+ years of oncology experience with comprehensive clinical development experience in global Phase I-III studies from start up to registration. Ex Senior Clinical Program Lead at Genentech, one of the world’s most successful biotech businesses developing therapies across all cancer indications. Previously at global majors GSK and Exelixis in cancer therapy development. Development experience in oncology with small molecules, immunotherapies, cancer vaccines, oncolytic viraltherapies, epigenetics and monoclonal antibodies. Extensive experience in leading clinical development of brain cancer therapies. Ms Chong is currently Chief Executive Officer and Managing Director of Imugene (ASX:IMU) and Non-Executive Director of Cure Brain Cancer Foundation (CBCF).
Ms Cindy Elkins
Elkins was Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers. Her role evolved into Head of Global CAR T Patient Experience, responsible for connecting patients with their personalised medicine through world leading service and technology. Juno was acquired by major global pharmaceutical company Celgene Corporation in 2018 for $11 billion. Celgene was then acquired by Bristol-Myers Squibb in 2019 for $74 billion, the third largest pharmaceutical company acquisition ever.
Prior to Juno, Elkins was Vice-President of Pharma Informatics at Genentech/Roche, where she was instrumental in ensuring all technology systems/processes were ready as soon as the FDA approved new medicines such as Zelboraf®, Gazyva®, Cotellic® and Tecentriq®. In this role she led a team of over 900 people in 12 countries across the Americas. Prior to Genentech, she was VP and General Manager at Ariba, where she created the largest transacting B2B eCommerce network in the world that now transacts over $3.5T annually.